Formations et évènements

ESMO

L'IFCT à l'ESMO 2025 :

• Paclitaxel-bevacizumab +/- atezolizumab in advanced non-squamous NSCLC progressing after chemo-immunotherapy: IFCT-2201 ADAPTABLE randomized phase II trial - Late breaking abstract
  Speaker : E. Giroux-Leprieur (Boulogne-Billancourt, France)
   
• SMARC4, c-MET and PD-L1 expression in pN2 non-small cell lung cancer from LungART IFCT 0503 trial.
  Speaker : Diego Diaz-Jimenez (Villejuif, France)
  
  
• Efficacy of lorlatinib after failure of a first-line ROS1 tyrosine kinase inhibitor (ROS1 TKI) in patients (pts) with advanced ROS1-positive non-small cell lung cancer (ROS1+ NSCLC) (IFCT-2003 ALBATROS)
  Speaker : Michael Duruisseaux (Lyon, France)
  
  
• Central pathology review of thymic tumors: updated analysis of diagnostic concordance in the French RYTHMIC cohort
  Speaker : Álvaro López Gutiérrez (Salamanca, Spain)
  
  
• CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses
  Speaker : Glenwood Goss (Ottawa, Canada, Ontorio)